Study of LY2157299 in Japanese Participants With Cancer

NCT01722825 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms
Neoplasm Metastasis

Interventions

DRUG: LY2157299

Sponsor

Eli Lilly and Company